109.92
price up icon0.44%   0.48
after-market Handel nachbörslich: 109.92
loading
Schlusskurs vom Vortag:
$109.44
Offen:
$109.62
24-Stunden-Volumen:
774.71K
Relative Volume:
0.65
Marktkapitalisierung:
$6.84B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
15.48
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
+2.61%
1M Leistung:
+1.51%
6M Leistung:
-11.18%
1J Leistung:
+4.60%
1-Tages-Spanne:
Value
$108.88
$110.69
1-Wochen-Bereich:
Value
$105.26
$111.25
52-Wochen-Spanne:
Value
$95.49
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
Firmenname
Jazz Pharmaceuticals Plc
Name
Telefon
353-1-634-7800
Name
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
Mitarbeiter
2,800
Name
Twitter
@jazzpharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
JAZZ's Discussions on Twitter

Vergleichen Sie JAZZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
109.92 6.84B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-07 Hochstufung UBS Neutral → Buy
2025-02-26 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-02-13 Hochstufung Wells Fargo Equal Weight → Overweight
2024-12-12 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-05 Eingeleitet Goldman Buy
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-11-27 Herabstufung UBS Buy → Neutral
2023-09-29 Eingeleitet Raymond James Mkt Perform
2023-06-12 Fortgesetzt Wells Fargo Equal Weight
2022-12-09 Hochstufung Goldman Neutral → Buy
2022-06-14 Eingeleitet UBS Buy
2022-04-06 Herabstufung Goldman Buy → Neutral
2021-11-19 Fortgesetzt Goldman Buy
2021-10-07 Fortgesetzt Jefferies Buy
2021-10-05 Eingeleitet Citigroup Buy
2021-09-23 Eingeleitet Needham Buy
2021-05-19 Fortgesetzt JP Morgan Overweight
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-05 Bestätigt H.C. Wainwright Buy
2021-02-03 Hochstufung Piper Sandler Neutral → Overweight
2021-01-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-12-16 Eingeleitet UBS Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-10-09 Bestätigt H.C. Wainwright Buy
2020-09-14 Herabstufung Goldman Neutral → Sell
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-06 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-07-28 Hochstufung Wolfe Research Peer Perform → Outperform
2020-07-23 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-06 Eingeleitet Jefferies Buy
2020-03-12 Hochstufung Bernstein Mkt Perform → Outperform
2020-01-08 Eingeleitet Goldman Neutral
2019-08-21 Herabstufung Piper Jaffray Overweight → Neutral
2019-06-11 Eingeleitet Barclays Overweight
2019-03-20 Eingeleitet SunTrust Buy
2018-12-14 Eingeleitet Wolfe Research Peer Perform
2018-11-08 Bestätigt B. Riley FBR Buy
2018-08-08 Bestätigt Stifel Buy
2018-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-03-23 Bestätigt H.C. Wainwright Neutral
2018-03-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
Alle ansehen

Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten

pulisher
Jun 19, 2025

FDA Approvals and Clinical Trials Impacting Narcolepsy - openPR.com

Jun 19, 2025
pulisher
Jun 13, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jun 13, 2025
pulisher
Jun 12, 2025

Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com

Jun 12, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Transcript : Jazz Pharmaceuticals plcSpecial Call - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

FDA Fast-Tracks Revolutionary Lung Cancer Drug That Cuts Disease Progression Risk by 46% - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLE - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire

Jun 09, 2025
pulisher
Jun 09, 2025

Jazz Pharmaceuticals' Xywav Achieves 4.1 mmHg Blood Pressure Reduction in Groundbreaking Phase 4 Trial - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Zepzelca combo extends survival in lung cancer study - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider

Jun 02, 2025
pulisher
Jun 02, 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire

Jun 02, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.

May 30, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire

May 29, 2025

Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Jazz Pharmaceuticals Plc-Aktie (JAZZ) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
COZADD BRUCE C
Chairman & CEO
Jun 02 '25
Sale
107.90
500
53,950
438,473
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):